Hsp90 inhibition sensitizes DLBCL cells to cisplatin

Linnéa Schmidt(Aalborg University Hospital), Karen Dybkær(Aalborg University Hospital), Jonas Laugård Hald(Aalborg University Hospital), Alexander Schmitz(Chr. Hansen (Denmark)), Hanne Due(Aalborg University Hospital), Issa Ismail Issa(Aalborg University Hospital), Hulda Haraldsdóttir(Aalborg University Hospital)

Cancer Chemotherapy and Pharmacology

February 21, 2022

10.1007/s00280-022-04407-5

Cited by 15

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2012|396

Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma

|Blood|2009|390

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

|Leukemia|2012|362

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2013|247